2007
COURSE #1 - STUDY DIRECTOR TRAINING – ALL DAY
Chair: Barbara J. Mounho, Ph.D., DABT, Toxicologist Research Scientist, Amgen
Inc., Thousand Oaks, CA
COURSE #2 - RISK ASSESSMENT: CURRENT PRACTICES AND FUTURE
DIRECTIONS – ALL DAY
Chair: Annette M. Shipp, Ph.D., Principal, ENVIRON International Corporation,
Ruston, LA
COURSE #3 - CARDIOVASCULAR ASSESSMENT: THE PRECEDING,
CONTEMPORARY AND PROSPECTIVE VIEWPOINT
Co-Chairs: Alfred N. Botchway, Ph.D., President, Xenometrics, LLC, Stilwell, KS
and Elaine V. Knight, Ph.D., Research Fellow, Johnson & Johnson
Pharmaceutical Research & Development, LLC, Raritan, NJ
COURSE #4 - RESPIRATORY DRUG DEVELOPMENT - A REVIEW OF
CURRENT KNOWLEDGE
Chair: Norman Kim, M.S., DABT, Inotek Pharmaceuticals Corporation,
Beverly, MA
COURSE #5 - APPLICATION OF THE HUMAN RELEVANCE FRAMEWORK
TO THE ANALYSIS OF RODENT TUMOR DATA
Co-Chairs: Jerry F. Hardisty, DVM, DACVP, Fellow IATP, President/Veterinary
Pathologist, EPL Inc., Research Triangle Park, NC and Douglas C. Wolf, DVM,
Ph.D., Fellow IATP, Staff Scientist, US EPA, Environmental Carcinogenesis Division,
Natl Health & Environmental Effects Research Laboratory, Research Triangle Park,
NC
COURSE #6 - SCREENING FOR DRUG ABUSE POTENTIAL: GUIDELINES
AND EXPECTATIONS
Chair: Gene E. Schulze, Ph.D., DABT, Group Director, Dept. of Toxicology,
Bristol-Myers Squibb Company, Syracuse, NY
SYMPOSIUM I - WHAT YOU ALWAYS WANTED TO KNOW ABOUT REACH;
BUT WERE AFRAID TO ASK
Co-Chairs: James C. Lamb, IV, Ph.D., DABT, Senior Vice President, The
Weinberg Group, Washington DC and Michael Holsapple, Ph.D., ATS, Executive
Director, ILSI / HESA, Washington, DC
SYMPOSIUM II - INHALATION TOXICOLOGY: TECHNOLOGICAL AND
REGULATORY TIPS OF THE TRADE
Co-Chairs: Hilary Sheevers, Ph.D., President, CEO, Aclairo Pharmaceutical
Development Group, Inc., Vienna, VA and Theresa Sweeney, Ph.D., Director Life
Sciences, Nektar Therapeutics, San Carlos, CA
SYMPOSIUM III - USE OF NON-MAMMALS FOR TOXICOLOGICAL AND
DRUG DISCOVERY STUDIES
Chair: Michael Ashner, Ph.D., Professor, Vanderbilt University Medical Center,
Nashville, IL
SYMPOSIUM IV - COMBINATION TOXICOLOGY
Co-Chairs: Melissa Rhodes, Ph.D., Project Manager, Safety Assessment,
GlaxoSmithKline, Research Triangle Park, NC and Michael Wyde, Ph.D.,
DABT, Toxicologist, NTP, Research Triangle Park, NC
SYMPOSIUM V- BUILDING COMPREHENSIVE IN VITRO SCREENING
APPROACHES FOR PREDICTING ANIMAL AND HUMAN TOXICITY:
IMPROVING THE DRUG SELECTION PROCESS
Co-Chairs: James M. McKim, IV, Ph.D., DABT, President/CEO, CeeTox,
Inc., Kalamazoo, MI and Edward LeCluyse, Ph.D., Chief Scientific Officer,
CellzDirect, Pittsboro, NC
SYMPOSIUM VI - THE IMPACT OF IMMUNOTOXICITY ON MOVING
PHARMACEUTICAL PRODUCTS THROUGH CLINICAL DEVELOPMENT
Co-Chairs: Marque D. Todd, DVM, DABT, Principal Scientist, Amgen Inc.,
Thousand Oaks, CA and Barbara Mounho, Ph.D., DABT, Principal Scientist,
Amgen Inc., Thousand Oaks, CA
SYMPOSIUM VII - SAFETY PHARMACOLOGY
Co-Chairs: Stephen Wilson , Scientist I, Safety Sciences, Charles River
Laboratories, Worcester, MA and Kenneth J. Olivier Jr., Ph.D., Project
Manager/Investigative Toxicologist, GlaxoSmithKline, Research Triangle
Park, NC
SYMPOSIUM VIII - PEDIATRIC INITIATIVES AND CONCERNS
Co-Chairs: Mildred S. Christian, Ph.D., Fellow, ATS, President, Argus
International, Inc., Horsham, PA and Alan B. Hoberman, Ph.D., Fellow, ATS,
DABT, General Manager, Charles River Laboratories - PA,
Horsham, PA
SYMPOSIUM IX - SMOKING AND CHRONIC OBSTRUCTIVE PULMONARY
DISEASE: STATE OF KNOWLEDGE AND FUTURE DISCUSSIONS
Co-Chairs: Willie J. McKinney, Ph.D., DABT, Principal Scientist, Philip Morris
USA, Richmond, VA and Chris Coggins, Ph.D., DABT, Consultant, Carson
Watts Consulting, King, NC
SYMPOSIUM X - CURRENT TRENDS AND ADVANCEMENT IN
ENVIRONMENTAL CHEMICAL RISK ASSESSMENT
Co-Chairs: Richard Phillips, ExxonMobil Petroleum & Chemical, Machelen,
Belgium and Richard A. Becker, American Chemistry Council, Arlington, VA
SYMPOSIUM XI - DERMAL ABSORPTION: AN IMPORTANT CONSIDERATION
FOR RISK ASSESSMENT - MODELS AND THEIR APPLICATIONS
Co-Chairs: Jon F. Lalko, B.S., Senior Program Specialist, Human Health,
RIFM, Inc. Woodcliff Lake, NJ and Daniel Isola, Newburgh, NY
SYMPOSIUM XII - TOXICOLOGIC CONSIDERATIONS IN THE TREATMENT
OF OBESITY
Chair: Tracey Zoetis, M.S., Managing Consultant, SciLucent, LLC, Herndon, VA
SYMPOSIUM XIII - STRESS AS A CONFOUNDING FACTOR IN THE
CONDUCT AND INTERPRETATION OF TOXICOLOGICAL STUDIES
Co-Chairs: Jerry F. Hardisty, DVM, DACVP, President, EPL, Inc.,
Research Triangle Park, NC and L.D. Hopper, DVM, Ph.D., DABT,
Director of Toxicology, BASi, Mount Vernon, IN
SYMPOSIUM XIV - REPRODUCTIVE AND DEVELOPMENTAL RISK
ASSESSMENT FOR BIOLOGICS IN THE NONHUMAN PRIMATE MODEL:
WHEN AND HOW SHOULD STUDIES BE CONDUCTED?
Co-Chairs: Gerhard Weinbauer, Ph.D., Director, Research and Safety
Assessment, Covance Laboratories GmbH, Muenster, Germany and
Barbara J. Mounho, Ph.D., DABT, Principal Scientist, Amgen Inc.,
Thousand Oaks, CA
SYMPOSIUM XV - EXPERIENCES WITH MICRODOSING TRIALS
Co-Chairs: Melissa Rhodes, Ph.D., Project Manager, Safety Assessment,
GlaxoSmithKline, Research Triangle Park, NC and Colin Garner, Bpharm,
Ph.D., D.Sc., FRCPath, Founder and CEO, Xceleron Inc., Heslington, UK
SYMPOSIUM XVI - SAFETY EVALUATION OF OCULAR DRUGS FOR
RETINAL DISEASES: FOCUS ON STRATEGIES AND PRACTICAL
APPROACHES
Co-Chairs: Brian Short, VDM, Ph.D., DACVP, Senior Director, Pathology,
Allergan, Inc., Irvine, CA and Andrea Weir, Ph.D., DABT, Senior Scientific
Advisor, Charles River Laboratories, Navigators, Sparks, NV
SYMPOSIUM XVII - HOT TOPICS IN DRUG DEVELOPMENT
Co-Chairs: Drew Badger, Ph.D., DABT, Director, Discovery Toxicology
and Scientific Operations, Allergan, Inc., Irvine, CA and Mary Ellen
Cosenza, Ph.D., DABT, RAC, Executive Director, Regulatory Affairs,
Amgen Inc., Thousand Oaks, CA
SYMPOSIUM XVIII - CONDUCTING NONCLINICAL TOXICOLOGY STUDIES
IN CHINA: OPPORTUNITIES, ISSUES, AND CONCERNS
Co-Chairs: Vincent L. Reynolds, Ph.D., DABT, Principal Research Toxicologist,
Eli Lilly and Company, Greenfield, IN and William Chen, Ph.D., DABT, Professor,
China Agricultural University, Beijing, PRC